Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Clinical trial NCT02923986 · WITHDRAWN

Trial details

NCT number

NCT02923986

Sponsor

Bio-Path Holdings, Inc.

Status

WITHDRAWN

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2017-09-01

Primary completion

2020-05-27

Enrollment

0

View on ClinicalTrials.gov